Comparative Pharmacology
Head-to-head clinical analysis: TROSPIUM CHLORIDE versus VESICARE LS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TROSPIUM CHLORIDE versus VESICARE LS.
TROSPIUM CHLORIDE vs VESICARE LS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tropium chloride is a quaternary ammonium compound that acts as a competitive antagonist at muscarinic acetylcholine receptors (M1, M2, M3), thereby reducing smooth muscle tone in the bladder, decreasing detrusor overactivity, and increasing bladder capacity.
Competitive antagonist at muscarinic acetylcholine receptors (M1–M5), with high selectivity for M3 receptors in the bladder detrusor muscle. Reduces involuntary bladder contractions and increases bladder capacity.
20 mg orally twice daily, extended-release 60 mg orally once daily in the morning.
5 mg orally once daily; may increase to 10 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 10-20 hours (mean 14 hours); clinical context: supports twice-daily dosing
Terminal elimination half-life: 45 hours (range 32–68 h). Extended half-life allows once-daily dosing; steady-state reached in ~10 days.
Renal: 65% (40% unchanged, 25% as metabolites); Fecal/Biliary: 35% (primarily via bile)
Renal: 68% (unchanged drug ~59%, metabolites ~9%), Fecal: 24% (metabolites), Biliary: negligible.
Category A/B
Category C
Anticholinergic
Anticholinergic